Getting Your Patient Started

Type sizer A A

Getting patients started with a MIRAPEX trial prescription package

Patients should be started on a trial prescription for the first two dosage strengths of MIRAPEX:

Ascending Dosage Schedule of MIRAPEX for RLS⁹

^†If needed

MIRAPEX tablets should be taken once daily, 2 to 3 hours before bedtime
MIRAPEX may be taken with or without food
Recommended starting dose is 0.125 mg once daily
If needed, dose may be increased every 4 to 7 days
Clinical trials included up to 0.75 mg per day
- There is no evidence that the 0.75 mg dose provides additional benefit beyond the 0.5 mg dose
In RLS patients with severe and moderate renal impairment (creatinine clearance 20-60 mL/min), the duration between titration steps should be increased to 14 days

Tracking RLS symptoms

It is important that healthcare providers instruct patients to track their symptoms during titration. This will help determine which MIRAPEX dosage is right for an individual. The MIRAPEX trial prescription package contains a helpful tool to assist patients with tracking their symptoms:

An RLS Doctor Discussion Guide/Patient Symptom & Sleep Diary to help patients track their symptoms for dosage purposes
Download a PDF

You will need Adobe^® Reader^® to download this file. If you don't have Adobe Reader, click here for a free and secure download.

Patient Education

Download tools to educate patients about Restless Legs Syndrome (RLS) and MIRAPEX. Find out more

MIRAPEX is now indicated for moderate-to-severe primary Restless Legs Syndrome.

MIRAPEX is now indicated for moderate-to-severe primary Restless Legs Syndrome. Learn more

Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

Patients have reported falling asleep without perceived warning signs during activities of daily living, including operation of a motor vehicle, which sometimes resulted in accidents. Hallucinations and postural (orthostatic) hypotension may occur. In clinical trials for RLS, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea (16% vs. 5%), headache (16% vs. 15%), fatigue (9% vs. 7%) and somnolence (6% vs. 3%).

Patients and caregivers should be informed that impulse control disorders and compulsive behaviors have been reported in patients taking dopamine agonists, including MIRAPEX.

This information is intended for U.S. residents only. Products discussed herein may have different labeling in different countries.

Please see full Prescribing Information, including patient information.